Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs TVTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PVLA Captures Overall Composite Edge (48.2 HOLD vs 60.4 BUY), While TVTX Leads 5–1 on Growth & Valuation Pillars

PVLA Overall Winner 6-Pillar Tally: PVLA 1 – 5 TVTX Matrix Metrics: PVLA 4 – 6 TVTX

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Travere Therapeutics, Inc. (TVTX) on higher Unified Composite conviction (48.2/100 HOLD vs. 60.4/100 BUY) after splitting the core matrix 4–6 (led by Profitability & Quality), while TVTX wins 5–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus TVTX at $49.90 (9.3x Forward P/E, -3.1% operating margin).

  • Composite vs. Pillar Nuance: While TVTX currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.1% operating margin) and revenue trajectory (+0.0% vs. +36.2% YoY).
  • Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile TVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs TVTX
PVLA NASDAQ Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
TVTX NASDAQ
Travere Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$49.90
-1.48% 1D
Market Cap $4.9B
TTM Revenue $651M
Forward P/E 9.3x
Beta / 30D Vol 1.39β · 44% Vol
Unified Composite Score
60.4 / 100 BUY
Tech 47.0 Fund 58.0 Flow 64.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 42
RSI-14: 41.8 · SMA20: $50.87 · SMA50: $55.62

6-Pillar Scorecard Institutional Category Breakdown (PVLA 1 – 5 TVTX)

Columns: Metric · PVLA · TVTX
1. Valuation Multiples TVTX
Forward P/E N/M 9.3x
Trailing P/E N/M 25.8x
PEG Ratio N/M N/M
EV / Revenue N/M 8.4x
2. Growth & Scale TVTX
Revenue Growth (YoY) +0.0% +36.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $651M
Market Cap $2.2B $4.9B
3. Profitability & Quality PVLA
Gross Margin N/A 61.1%
Operating Margin 0.0% -3.1%
Net Profit Margin 0.0% -18.7%
Return on Equity (ROE) -63.4% -321.2%
4. Balance Sheet & Cash Flow TVTX
Cash Generation (TTM) -$43M -$27M
Cash Flow Margin N/A -4.2%
Net Cash / Leverage $193M Net Cash $493M Net Debt (27.28x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TVTX
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 47.9% (2nd %ile) 39.1% (6th %ile)
Put/Call OI Skew 3.82x (Put-Skewed) 0.05x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat TVTX
OpEx & R&D Intensity N/A 64.2% of Rev ($418M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (4) vs TVTX (6)
Institutional Metric PVLA TVTX Criterion Row Edge
Market Capitalization
Scale
$2.2B $4.9B Larger Scale TVTX
Trailing P/E Ratio
Valuation
N/M 25.8x Lower Multiple TVTX
Forward P/E Ratio
Valuation
N/M 9.3x Lower Multiple TVTX
Revenue Growth (YoY)
Growth
+0.0% +36.2% Higher Growth TVTX
Operating Margin (TTM)
Profitability
0.0% -3.1% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% -18.7% Higher Margin PVLA
Return on Equity (ROE)
Capital Efficiency
-63.4% -321.2% Higher ROE PVLA
52-Week Range Position
Momentum
68% ($72–$180) 59% ($23–$69) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 1.39β · 44% Vol Lower Realized Risk TVTX
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 60.4 / 100 (BUY) Higher Composite TVTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $651M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 61.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 8.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$27M ($493M Net Debt (27.28x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +19.96 pp
PVLA: +20.56% · TVTX: +0.6%
3M Horizon PVLA +18.33 pp
PVLA: -3.58% · TVTX: -21.91%
6M Horizon PVLA +21.72 pp
PVLA: +38.06% · TVTX: +16.34%
1Y Horizon PVLA +32.92 pp
PVLA: +80.16% · TVTX: +47.24%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PVLA Revenue TVTX Revenue PVLA Op. Margin TVTX Op. Margin Margin Leader
FY2018 $30M $160M -113.1% -48.7% TVTX
FY2019 $40M $180M -62.2% -78.3% PVLA
FY2020 $30M $200M -115.7% -88.8% TVTX
FY2021 $30M $130M -165.0% -151.3% TVTX
FY2022 $30M $110M -167.8% -292.2% PVLA
FY2023 $40M $150M -27.7% -267.2% PVLA
FY2024 N/A $230M N/A -138.9% TVTX
FY2025 N/A $490M N/A -12.8% TVTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TVTX CONSOLIDATION
101d in phase · OBV ACCUMULATION
Current IV 39.1%
IV Percentile 6th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TVTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.9B market capitalization and -3.1% operating margin.
OpEx & R&D Reinvestment 64.2% of Rev ($418M)
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs TVTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Travere Therapeutics, Inc. (TVTX) on higher Unified Composite conviction (48.2/100 HOLD vs. 60.4/100 BUY) after splitting the core matrix 4–6 (led by Profitability & Quality), while TVTX wins 5–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus TVTX at $49.90 (9.3x Forward P/E, -3.1% operating margin). Composite vs. Pillar Nuance: While TVTX currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.1% operating margin) and revenue trajectory (+0.0% vs. +36.2% YoY). Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile TVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TVTX leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TVTX at +36.2% YoY revenue growth and +0.0% YoY earnings growth on $651M TTM revenue (61.1% gross margin, -3.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PVLA cumulative revenue shifted +33.3% while TVTX shifted +206.2%. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus 64.2% of Rev ($418M) (0 disclosures) for TVTX.

TVTX screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TVTX trades at 9.3x Forward P/E, 25.8x Trailing P/E, N/M PEG, and 8.4x EV/Revenue (-4.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus TVTX (-321.2% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, TVTX carries 39.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.39β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.